BioMarin Pharmaceutical (BMRN)
(Real Time Quote from BATS)
$84.43 USD
-1.46 (-1.70%)
Updated Jul 17, 2024 02:06 PM ET
4-Sell of 5 4
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BMRN 84.43 -1.46(-1.70%)
Will BMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?
Other News for BMRN
Parnassus Mid Cap Fund Q2 2024 Investment Commentary
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Wall Street Analysts Are Bullish on Top Healthcare Picks
BioMarin price target raised by $4 at Wells Fargo, here's why